Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency
Authors:
- B. KuhnBKB. Kuhn
- B. KränzlinBKB. Kränzlin
- M. SadickMSM. Sadick
- J. GrossJGJ. Gross
- N. GretzNGN. Gretz
- J. PillJPJ. Pill
- 1 January 2006
- journal article
- Published by Elsevier in Kidney International
- Vol. 69 (1) , 60-67
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004
- Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trialKidney International, 2004
- Erythropoietin resistance: the role of inflammation and pro‐inflammatory cytokinesNephrology Dialysis Transplantation, 2002
- The clinical potential of novel erythropoiesis stimulating proteinExpert Opinion on Biological Therapy, 2001
- Anemia management of adult hemodialysis patients in the U.S.: Results from the 1997 ESRD Core Indicators ProjectKidney International, 2000
- Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failureKidney International, 1997
- Rheological properties of erythrocytes in recombinant human erythropoietin‐administered normal ratBritish Journal of Haematology, 1989
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986
- Immunogenicity of polyethylene glycol-modified superoxide dismutase and catalaseJournal of Free Radicals in Biology & Medicine, 1986